Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › alirocumab

alirocumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of alirocumab

30 trials tracked of alirocumab: 23 in phase 3 or 4 and 11 with published results. The most-cited published study has 196 citations.

30Trials tracked
23Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 2 Phase 3 21 Phase 2 6 Phase 1 1
  1. Phase 3 Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy Completed · 196 cited
  2. Phase 3 Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) Completed · 164 cited
  3. Phase 3 Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) Completed · 140 cited
  4. Phase 4 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed · 126 cited
  5. Phase 3 Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan Completed · 126 cited
  6. Phase 3 Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) Completed · 124 cited
Show 24 more trials
  1. Phase 3 Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II) Completed · 102 cited
  2. Phase 3 Open Label Study of Long Term Safety Evaluation of Alirocumab Completed · 58 cited
  3. Phase 3 Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Completed · 49 cited
  4. Phase 3 Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin Completed · 22 cited
  5. Phase 3 ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Completed · 22 cited
  6. Phase 4 Alirocumab in Patients With Acute Myocardial Infarction Completed
  7. Phase 3 Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) Completed
  8. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I) Completed
  9. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II) Completed
  10. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy Completed
  11. Phase 3 Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) Completed
  12. Phase 3 Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) Completed
  13. Phase 3 Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) Completed
  14. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia Completed
  15. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) Completed
  16. Phase 3 Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Completed
  17. Phase 3 Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term) Completed
  18. Phase 2 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia Completed
  19. Phase 2 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan Completed
  20. Phase 2 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy Completed
  21. Phase 2 Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) Completed
  22. Phase 2 Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia Completed
  23. Phase 2 A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene Completed
  24. Phase 1 Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD
Cardiology Phase III
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD Re-analysis suggests most PCSK9 inhibitor benefit comes from lowering Lp(a)
This Phase 3 corrective re-analysis of cardiovascular outcomes trial data in secondary prevention populations with ASCVD evaluated the role …
Researchers re-analyzed data from Phase 3 trials of alirocumab and evolocumab in patients with atherosclerotic cardiovascular disease.
medRxiv Apr 16, 2026